Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Fulcrum Therapeutics (FULC)
:FULC
FULC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.86 - $13.70
Previous CloseN/A
Volume345.04K
Average Volume (3M)467.50K
Market Cap
$203.35M
Enterprise Value-$25.29M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Feb 25, 2025EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding53,938,660
10 Day Avg. Volume358,935
30 Day Avg. Volume467,505
Standard Deviation0.51
R-Squared0.04
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.51
Price to Cash Flow (P/CF)-2.70
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-9.02
Enterprise Value/Ebitda1.07
Forecast
1Y Price Target
$7.33Price Target Upside90.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Fulcrum Therapeutics News
PremiumCompany Announcements
Fulcrum Therapeutics Advances Pociredir for Sickle Cell Disease
PremiumCompany Announcements
Fulcrum Therapeutics Faces Genzyme Agreement Termination
PremiumCompany Announcements
Fulcrum Therapeutics Reports Q3 2024 Financial Progress
PremiumPre-Earnings
Is FULC a Buy, Before Earnings?---
Bulls Say, Bears Say
Bulls Say
Investor InterestRenewed interest in pociredir’s potential in sickle cell disease (SCD) has emerged following Pfizer’s recent withdrawal of Oxbryta from the market, which has reinvigorated investor discussions about pociredir’s opportunity in this space.
Market OpportunityThe withdrawal of Oxbryta from the market due to safety concerns creates an interesting dynamic for FULC, underscoring the need for additional SCD therapies and potentially making more patients eligible for the PIONEER study.
Trial Activation And EnrollmentFULC seems to finally be getting good traction with site activation and trial enrollment for pociridir in sickle cell disease.
Bears Say
Stock DowngradeWe downgrade Fulcrum Therapeutics (FULC) shares to Underperform from Neutral.
Trial FailureFULC announced that their lead program losmapimod did not meet its primary or secondary endpoints in its FSHD pivotal trial and the program has been discontinued.
Valuation And Market PerceptionFulcrum's stock is expected to continue to trade closer to cash until further clarity on the pipeline is garnered.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
FULC FAQ
What was Fulcrum Therapeutics’s price range in the past 12 months?
Fulcrum Therapeutics lowest stock price was $2.86 and its highest was $13.70 in the past 12 months.
What is Fulcrum Therapeutics’s market cap?
Fulcrum Therapeutics’s market cap is $203.35M.
When is Fulcrum Therapeutics’s upcoming earnings report date?
Fulcrum Therapeutics’s upcoming earnings report date is Feb 25, 2025 which is in 4 days.
How were Fulcrum Therapeutics’s earnings last quarter?
Fulcrum Therapeutics released its earnings results on Nov 13, 2024. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.396 by $0.046.
Is Fulcrum Therapeutics overvalued?
According to Wall Street analysts Fulcrum Therapeutics’s price is currently Undervalued.
Does Fulcrum Therapeutics pay dividends?
Fulcrum Therapeutics does not currently pay dividends.
What is Fulcrum Therapeutics’s EPS estimate?
Fulcrum Therapeutics’s EPS estimate is -0.28.
How many shares outstanding does Fulcrum Therapeutics have?
Fulcrum Therapeutics has 53,938,660 shares outstanding.
What happened to Fulcrum Therapeutics’s price movement after its last earnings report?
Fulcrum Therapeutics reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.396. Following the earnings report the stock price went down -2.198%.
Which hedge fund is a major shareholder of Fulcrum Therapeutics?
Currently, no hedge funds are holding shares in FULC
---
Fulcrum Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.33 (90.89% Upside)
$7.33 (90.89% Upside)
Blogger Sentiment
Bullish
FULC Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.16%
12-Months-Change
Fundamentals
Return on Equity
-6.99%
Trailing 12-Months
Asset Growth
0.05%
Trailing 12-Months
Company Description
Fulcrum Therapeutics
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.
---
FULC Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented some key positive developments, such as a strong financial position, progress in the pociredir program, and strategic leadership changes. However, these were balanced by significant setbacks, including the suspension of the losmapimod program and a notable workforce reduction. The financial outlook remains stable, despite zero collaboration revenue and a net loss. Overall, the call reflects a balanced sentiment with both positive and negative elements.Read More>---
FULC Stock 12 Month Forecast
Average Price Target
$7.33
▲(90.89% Upside)
Technical Analysis
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Bluebird Bio
―
Editas Medicine
―
Crispr Therapeutics AG
―
Best Analysts Covering FULC
1 Year
1 Year Success Rate
6/12 ratings generated profit
1 Year Average Return
+19.78%
reiterated a buy rating 3 months ago
Copying Matthew Biegler's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +19.78% per trade.
---